Comparative review of the pharmacokinetics of vitamin D analogues

被引:43
作者
Bailie, GR
Johnson, CA
机构
[1] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA
[2] Albany Coll Pharm, Albany, NY USA
关键词
D O I
10.1046/j.1525-139X.2002.00086.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This article reviews the pharmacokinetic characteristics of calcitriol, paricalcitol, and doxercalciferol, and provides an overview of the metabolism of vitamin D. Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis. Both are active on intravenous administration and little of the active agent remains in the circulation after 24 hours, although they are normally given every 48-72 hours. Doxercalciferol is a prohormone, requiring hepatic metabolism to the active metabolite 1alpha,25-(OH)(2) D-2. The half-life of 1alpha,25-(OH) (2) D-2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D. More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients.
引用
收藏
页码:352 / 357
页数:6
相关论文
共 20 条
[1]   No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism [J].
Ardissino, G ;
Schmitt, CP ;
Bianchi, ML ;
Daccò, V ;
Claris-Appiani, A ;
Mehls, O .
KIDNEY INTERNATIONAL, 2000, 58 (03) :981-988
[2]  
ASH SR, 1997, J AM SOC NEPHROL, V88, P1587
[3]   No difference in intestinal strontium absorption after an oral or an intravenous 1,25(OH)2D3 bolus in normal subjects [J].
Bianchi, ML ;
Ardissino, GL ;
Schmitt, CP ;
Daccó, V ;
Barletta, L ;
Claris-Appiani, A ;
Mehls, O .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (10) :1789-1795
[4]   SERUM-PROTEIN BINDING OF 1,25-DIHYDROXYVITAMIN-D - A REEVALUATION BY DIRECT MEASUREMENT OF FREE METABOLITE LEVELS [J].
BIKLE, DD ;
SIITERI, PK ;
RYZEN, E ;
HADDAD, JG ;
GEE, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 61 (05) :969-975
[5]   Effect of hemodialysis on the pharmacokinetics of 19-nor-1α,25-dihydroxyvitamin D2 [J].
Cato, A ;
Cady, WW ;
Soltanek, C ;
Qasawa, B ;
Chang, M ;
Stoll, R .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :S55-S60
[6]  
Cato A. Iii, 1997, Clinical Pharmacology and Therapeutics, V61, P218
[7]   THE EFFECTS OF INTRAPERITONEAL CALCITRIOL ON CALCIUM AND PARATHYROID-HORMONE [J].
DELMEZ, JA ;
DOUGAN, CS ;
GEARING, BK ;
ROTHSTEIN, M ;
WINDUS, DW ;
RAPP, N ;
SLATOPOLSKY, E .
KIDNEY INTERNATIONAL, 1987, 31 (03) :795-799
[8]   Mechanism of vitamin D action and its regulation [J].
Dusso, AS ;
Brown, AJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :S13-S24
[9]   CALCITRIOL METABOLISM IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
HSU, CH ;
PATEL, S ;
BUCHSBAUM, BL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 17 (02) :185-190
[10]  
JONES CL, 1994, CLIN NEPHROL, V42, P44